The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review
Standard
The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review. / Gagelmann, Nico; Kröger, Nicolaus.
in: ANN HEMATOL, Jahrgang 100, Nr. 2, 02.2021, S. 405-419.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review
AU - Gagelmann, Nico
AU - Kröger, Nicolaus
PY - 2021/2
Y1 - 2021/2
N2 - Despite the increasing inclusion of novel agents within the multiple myeloma (MM) treatment sequence, their role for posttransplant consolidation therapy remains unclear. We systematically reviewed studies evaluating the efficacy of novel agent consolidation. We identified 11 citations on 12 prospective comparative studies, and 5 citations were single-arm or comparative studies with preliminary results. Nine different regimens were evaluated in 5905 patients. Risk assessment yielded serious risk of bias and heterogeneity across study designs was high. Irrespective of the regimen, deepened responses after consolidation were seen and improvements were more pronounced with multi-agent consolidation. Bortezomib, thalidomide, and dexamethasone improved long-term survival versus duplet consolidation, including in patients with high-risk cytogenetics. The addition of daratumumab to triplet regimens yielded modestly improved responses with significantly increased rates of minimal residual disease negativity but survival results were limited by short follow-up. In high-risk MM, responses were not different, whereas progression-free survival appeared to be improved with consolidation therapy, challenging the association of response and overall outcome in this subgroup. Our findings highlight the necessity of longer follow-up and consistent reporting to ensure comparability of studies to enable better evidence assessment and to identify patients benefitting from consolidation therapy.
AB - Despite the increasing inclusion of novel agents within the multiple myeloma (MM) treatment sequence, their role for posttransplant consolidation therapy remains unclear. We systematically reviewed studies evaluating the efficacy of novel agent consolidation. We identified 11 citations on 12 prospective comparative studies, and 5 citations were single-arm or comparative studies with preliminary results. Nine different regimens were evaluated in 5905 patients. Risk assessment yielded serious risk of bias and heterogeneity across study designs was high. Irrespective of the regimen, deepened responses after consolidation were seen and improvements were more pronounced with multi-agent consolidation. Bortezomib, thalidomide, and dexamethasone improved long-term survival versus duplet consolidation, including in patients with high-risk cytogenetics. The addition of daratumumab to triplet regimens yielded modestly improved responses with significantly increased rates of minimal residual disease negativity but survival results were limited by short follow-up. In high-risk MM, responses were not different, whereas progression-free survival appeared to be improved with consolidation therapy, challenging the association of response and overall outcome in this subgroup. Our findings highlight the necessity of longer follow-up and consistent reporting to ensure comparability of studies to enable better evidence assessment and to identify patients benefitting from consolidation therapy.
KW - Adult
KW - Aged
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Bortezomib/therapeutic use
KW - Consolidation Chemotherapy
KW - Dexamethasone/therapeutic use
KW - Female
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Male
KW - Middle Aged
KW - Multiple Myeloma/diagnosis
KW - Risk Assessment
KW - Thalidomide/therapeutic use
KW - Transplantation, Autologous
U2 - 10.1007/s00277-020-04316-8
DO - 10.1007/s00277-020-04316-8
M3 - SCORING: Review article
C2 - 33123798
VL - 100
SP - 405
EP - 419
JO - ANN HEMATOL
JF - ANN HEMATOL
SN - 0939-5555
IS - 2
ER -